| Bioactivity | Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine can be used for cancer research[1]. |
| Target | IC50: 0.4 μM (CDA) |
| Invitro | Cedazuridine (Compound 7a) exhibits superior acid stability[1].Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines[2]. |
| In Vivo | Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models[2]. Animal Model: |
| Name | Cedazuridine |
| CAS | 1141397-80-9 |
| Formula | C9H14F2N2O5 |
| Molar Mass | 268.21 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Ferraris D, et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 2014 Mar 27; 57(6):2582-8. [2]. Ramsey H E, et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Targeted Oncology, 2020, 15(2): 231-240. |
Cedazuridine
CAS: 1141397-80-9 F: C9H14F2N2O5 W: 268.21
Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM.
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.